Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duane D Miller

Showing results (81-90 of 246) with videos related to

Pageof 25
Sort By:
Medicinal Research Reviews|February 13, 2019
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapyKinsie E Arnst, Souvik Banerjee, Hao Chen, et al.
Journal of Medicinal Chemistry|February 24, 2023
Metabolism-Guided Selective Androgen Receptor Antagonists: Design, Synthesis, and Biological Evaluation for Activity against Enzalutamide-Resistant Prostate CancerDong-Jin Hwang, Yali He, Suriyan Ponnusamy, et al.
Drug Development Research|March 21, 2014
Quinic acid derivative KZ-41 exhibits radiomitigating activity in preclinical models of radiation injuryKarin E Thompson, Kui Zeng, Christy M Wilson, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2006
Tethered yohimbine analogs as selective human alpha2C-adrenergic receptor ligandsSupriya A Bavadekar, Guoyi Ma, Suni M Mustafa, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Synthesis and biological studies of yohimbine derivatives on human alpha2C-adrenergic receptorsSuni M Mustafa, Supriya A Bavadekar, Guoyi Ma, et al.
Journal of Cellular and Molecular Medicine|August 18, 2023
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastomaChuanhe Yang, Yali He, Yinan Wang, et al.
Expert Opinion on Drug Discovery|June 7, 2013
Novel approaches to glioma drug design and drug screeningShivaputra A Patil, Amira Hosni-Ahmed, Terreia S Jones, et al.
Journal of Medicinal Chemistry|October 23, 2020
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate CancerYali He, Dong-Jin Hwang, Suriyan Ponnusamy, et al.
Journal of Medicinal Chemistry|July 16, 2021
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate CancerYali He, Dong-Jin Hwang, Suriyan Ponnusamy, et al.
Journal of Cellular and Molecular Medicine|February 2, 2021
Brahma-Related Gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cellsYinan Wang, Chuan He Yang, Andrew P Schultz, et al.
Pageof 25

Showing results (81-90 of 246) with videos related to

Sort By:
Pageof 25
Medicinal Research Reviews|February 13, 2019
Current advances of tubulin inhibitors as dual acting small molecules for cancer therapyKinsie E Arnst, Souvik Banerjee, Hao Chen, et al.
Journal of Medicinal Chemistry|February 24, 2023
Metabolism-Guided Selective Androgen Receptor Antagonists: Design, Synthesis, and Biological Evaluation for Activity against Enzalutamide-Resistant Prostate CancerDong-Jin Hwang, Yali He, Suriyan Ponnusamy, et al.
Drug Development Research|March 21, 2014
Quinic acid derivative KZ-41 exhibits radiomitigating activity in preclinical models of radiation injuryKarin E Thompson, Kui Zeng, Christy M Wilson, et al.
The Journal of Pharmacology and Experimental Therapeutics|July 29, 2006
Tethered yohimbine analogs as selective human alpha2C-adrenergic receptor ligandsSupriya A Bavadekar, Guoyi Ma, Suni M Mustafa, et al.
Bioorganic & Medicinal Chemistry Letters|May 25, 2005
Synthesis and biological studies of yohimbine derivatives on human alpha2C-adrenergic receptorsSuni M Mustafa, Supriya A Bavadekar, Guoyi Ma, et al.
Journal of Cellular and Molecular Medicine|August 18, 2023
Next-generation bromodomain inhibitors of the SWI/SNF complex enhance DNA damage and cell death in glioblastomaChuanhe Yang, Yali He, Yinan Wang, et al.
Expert Opinion on Drug Discovery|June 7, 2013
Novel approaches to glioma drug design and drug screeningShivaputra A Patil, Amira Hosni-Ahmed, Terreia S Jones, et al.
Journal of Medicinal Chemistry|October 23, 2020
Pyrazol-1-yl-propanamides as SARD and Pan-Antagonists for the Treatment of Enzalutamide-Resistant Prostate CancerYali He, Dong-Jin Hwang, Suriyan Ponnusamy, et al.
Journal of Medicinal Chemistry|July 16, 2021
Exploration and Biological Evaluation of Basic Heteromonocyclic Propanamide Derivatives as SARDs for the Treatment of Enzalutamide-Resistant Prostate CancerYali He, Dong-Jin Hwang, Suriyan Ponnusamy, et al.
Journal of Cellular and Molecular Medicine|February 2, 2021
Brahma-Related Gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cellsYinan Wang, Chuan He Yang, Andrew P Schultz, et al.
Pageof 25